ERBB2 and neoplasm: In this sense, preclinical studies revealed that resistant tumor cells exhibited augmented levels of cyclin D1 and CDK4, and the subsequent addition of a CDK4/6 inhibitor restored cell sensitivity to HER2-targeted therapies [115].